 |
|
TGen researchers discover possible way to block the spread of deadly brain tumors
April 20, 2009Findings will be presented during the 100th annual meeting of the American Association for Cancer Research in Denver
Researchers at the Translational Genomics Research Institute (TGen) may have found a way to stop the often-rapid spread of deadly brain tumors.
A gene with the playful-sounding name NHERF-1 may be a serious target for drugs that could prevent malignant tumors from rapidly multiplying and invading other parts of the brain, according to a cover story in this month's edition of Neoplasia, an international journal of cancer research.
Cancer cell movement and rapid division are key characteristics of malignant brain tumors known as glioblastoma multiforme, or GBM.
Dr. Michael Berens, Director of TGen's Cancer and Cell Biology Division, said the recent findings are a major step toward devising a treatment for GBM, which because of its ability to rapidly grow within the brain often means patients have little time to survive.
"Controlling the actions of tumor cells by regulating NHERF-1 implicates it as a possible therapeutic target for treating brain cancer," said Dr. Kerri Kislin, a scientist in TGen's Cancer and Cell Biology Division.
"Our findings suggest a novel mechanism defining NHERF-1 as a 'molecular switch' that regulates the GBM tumor cell's ability to migrate or divide,'' said Dr. Kislin, the scientific paper's lead author.
Dr. Berens, the paper's senior author, said the advances made by TGen not only confirm NHERF-1 as a gene associated with brain tumors, but also pinpoint it as a possible cause for their rapid growth and spread of GBM.
"Dr. Kislin's work has meant a fast maturation of NHERF-1 from a candidate gene associated with glioma invasion to positioning it as having a verified role in contributing to the malignant behavior of the disease," Dr. Berens said.
TGen scientists are scheduled to present their findings at the 100th annual meeting of the American Association for Cancer Research, April 18-22 in Denver.
Glioblastomas are essentially incurable tumors, in part, because there is no way to remove them surgically and ensure that all of the invading tumor cells are gone, even when surgery is followed by radiation treatments and conventional anti-cancer drugs.
"A chemotherapeutic treatment which targets these migrating cells would therefore have significant ramifications on patient survival," said Dr. Jennifer M. Eschbacher, a Neuropathology Fellow at Barrow Neurological Institute, who examined tumors for the study.
"As a pathologist, I examined expression of NHERF-1 under the microscope in tumor sections, including both invading edges of tumor and cellular tumor cores. We found NHERF-1 to be robustly expressed by invading tumors cells, when compared to tumor cores, suggesting that this factor plays a significant role in tumor invasion,'' Dr. Eschbacher said.
In the study, depletion of NHERF-1 stopped the migration of glioma -- brain cancer -- cells, she said. "These results suggest that NHERF-1 plays an important role in tumor biology, and that targeted inhibition of this factor may have significant effects on patient treatment and survival.''
The Translational Genomics Research Institute
Cancer cell movement and rapid division are key characteristics of malignant brain tumors known as glioblastoma multiforme, or GBM.
Dr. Michael Berens, Director of TGen's Cancer and Cell Biology Division, said the recent findings are a major step toward devising a treatment for GBM, which because of its ability to rapidly grow within the brain often means patients have little time to survive.
"Controlling the actions of tumor cells by regulating NHERF-1 implicates it as a possible therapeutic target for treating brain cancer," said Dr. Kerri Kislin, a scientist in TGen's Cancer and Cell Biology Division.
"Our findings suggest a novel mechanism defining NHERF-1 as a 'molecular switch' that regulates the GBM tumor cell's ability to migrate or divide,'' said Dr. Kislin, the scientific paper's lead author.
Dr. Berens, the paper's senior author, said the advances made by TGen not only confirm NHERF-1 as a gene associated with brain tumors, but also pinpoint it as a possible cause for their rapid growth and spread of GBM.
"Dr. Kislin's work has meant a fast maturation of NHERF-1 from a candidate gene associated with glioma invasion to positioning it as having a verified role in contributing to the malignant behavior of the disease," Dr. Berens said.
TGen scientists are scheduled to present their findings at the 100th annual meeting of the American Association for Cancer Research, April 18-22 in Denver.
Glioblastomas are essentially incurable tumors, in part, because there is no way to remove them surgically and ensure that all of the invading tumor cells are gone, even when surgery is followed by radiation treatments and conventional anti-cancer drugs.
"A chemotherapeutic treatment which targets these migrating cells would therefore have significant ramifications on patient survival," said Dr. Jennifer M. Eschbacher, a Neuropathology Fellow at Barrow Neurological Institute, who examined tumors for the study.
"As a pathologist, I examined expression of NHERF-1 under the microscope in tumor sections, including both invading edges of tumor and cellular tumor cores. We found NHERF-1 to be robustly expressed by invading tumors cells, when compared to tumor cores, suggesting that this factor plays a significant role in tumor invasion,'' Dr. Eschbacher said.
In the study, depletion of NHERF-1 stopped the migration of glioma -- brain cancer -- cells, she said. "These results suggest that NHERF-1 plays an important role in tumor biology, and that targeted inhibition of this factor may have significant effects on patient treatment and survival.''
The Translational Genomics Research Institute
Brain Tumors Current Events and Brain Tumors News RSSBrain tumors in childhood leave a lasting mark on cognition, life status
Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.
The Largest Congress Worldwide on Ion Therapy in Heidelberg
The largest congress worldwide on the topic of particle or ion therapy - radiation with heavy ions and protons - has taken place in the fall of 2009 in Heidelberg.
Exercise can aid recovery after brain radiation
Exercise is a key factor in improving both memory and mood after whole-brain radiation treatments in rodents, according to data presented by Duke University scientists at the Society for Neuroscience meeting.
Researchers report benefits of new standard treatment study for rare pediatric brain cancer
A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor.
Unequal access: Hispanic children rarely get top-notch care for brain tumors
Hispanic children diagnosed with brain tumors get high-quality treatment at hospitals that specialize in neurosurgery far less often than other children with the same condition, potentially compromising their immediate prognosis and long-term survival, according to research from Johns Hopkins published in October's Pediatrics.
Survivors of childhood cancer less likely to marry
Childhood cancer survivors typically suffer from the long-term effects of cancer treatment on physical health, and results of a new study suggest that social implications also exist, which may affect their chance of an "I do" at the altar.
Stereotactic radiosurgery preferred method of treating cancer patients with brain metastases
Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone, according to researchers at The University of Texas M. D. Anderson Cancer Center.
New Approach for the Treatment of Malignant Brain Tumors
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence.
Why don't brain tumors respond to medication?
Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance.
Small peptide found to stop lung cancer tumor growth in mice
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
More Brain Tumors Current Events and Brain Tumors News Articles
 |
Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black (Author) Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors. This invaluable resource tells patients everything they need to know to understand and address their diagnosis, in a four-part structure: • “What is a Brain Tumor?" provides straightforward information about how brain tumors are diagnosed, the different types of tumors and how they develop, and where to go for treatment. • “Coping with Shock” addresses the emotional... |
 |
Curveball: When Life Throws You a Brain Tumor by Liz Holzemer (Author) Life seemed idyllic for thirty-two-year-old Liz Holzemer. Wife of Major League Baseball pitcher Mark Holzemer, Liz was enjoying a successful career as a journalist when an MRI revealed a baseball-size brain tumor she soon found out was called meningioma. Told with clarity and unwavering humor, this book is an inspirational and informative account of one woman’s battle for her life. It shows how she emerged from this frightening diagnosis and two brain surgeries retaining her remarkable spirit of survival and renewed sense of purpose and hope. With practical information about meningioma and brain surgery, Curveball is a manual for people who face life-altering challenges and is also proof that one need not fight such battles alone. |
 |
Guerilla Guide to Brain Tumors: Shameless Dirty Tricks to beat the system and STAY ALIVE! by Skip Goebel (Author) In an unprecedented format, the Guerilla Guide to Brain Tumors is written in a format that combines the layout of the For Dummies series with a drill-sargent's attitude. (the back page says it all) This is a book of War Nothing warm and fuzzy or socially acceptable here and nothing about "Dying with Dignity". Just what it takes to win. And win you will, complete with a trail of wreckage behind you. It's a book for the patient, NOT the caregiver. The Guerilla Guide to Brain Tumors is a book that will take you out of the "Grovel and Wretch" mode and into the "Command and Dominate" mode with the following factions of our society: The Medical EstablishmentThe Social Services EstablishmentChurch, Friends and FamilyAnd most importantly...Yourself No punches are pulled here. Prepare to be... |
 |
Brain Tumors: Leaving the Garden of Eden--A Survival Guide to Diagnosis, Learning the Basics, Getting Organized, and Finding Your Medical Team by Paul M. Zeltzer (Author) A guidebook for the 150,000+ people/ year and families affected by brain tumors. This book will help you learn the basics about diagnosis, getting organized and finding your medical team. Included are chapters on all major types of brain tumors & metastases, glossary, medications, using the Internet to search for information, and getting a second opinion. "Brain Tumors:Leaving the Garden of Eden" is all about improving your odds by gathering information, & assessing your situation: What you need to do; what you need to know; what you can do now! |
 |
Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by Harry Wolf (Author) June 3, 2002 was the day that changed my life forever. A 43-year-old father of three, whom in oneday went from being a successful senior manager to a man with a braintumor. I have a glioblastoma multiformegrade IV brain tumor, the most deadly and aggressive type of brain tumor. This book covers how I have dealt with lifeafter being informed that I have a tumor that only 1-2% survive for 2years. I share the experiences, thoughts,and events from my first year as a survivor. When I was first diagnosed, I searched for a book that covered thedetails of what could be expected on both a medical and personal level. I could not find, so I wrote one. I maintained a detailed journal. I cover the first surgery, an awakecraniotomy, and the subsequent head infection that led to a second... |
 |
Tumors of the Brain and Spine (M.D. Anderson Cancer Care Series) by Franco DeMonte (Editor), Mark R. Gilbert (Editor), Anita Mahajan (Editor), Ian E. McCutcheon (Editor), R. Sawaya (Editor), W.K.A. Yung (Editor) Tumors of the Brain and Spine focuses primarily on the standard approaches to the treatment of benign, primary low-grade to high-grade, and metastatic tumors in the brain and spine used by surgeons and clinicians at The University of Texas M. D. Anderson Cancer Center. It is written mainly for the primary care oncologist, general neurologist, and general neurosurgeon. Chapters on treatment focus on neurosurgery, chemotherapy, and radiation therapy, both singly and in combination. Chapters on symptom management, the molecular genetics and neuropathology of intracranial tumors, the leptomeningeal dissemination of systemic cancer, the epidemiology of brain tumors, and innovative treatment strategies round out the volume. |
 |
Dark Victory (Restored and Remastered Edition) Starring: Bette Davis, George Brent, Humphrey Bogart, Geraldine Fitzgerald, Ronald Reagan Directed By: Edmund Goulding Also With: Ernest Haller (Cinematographer), William Holmes (Editor), David Lewis (Producer), Hal B. Wallis (Producer), Bertram Bloch (Writer), Casey Robinson (Writer), George Emerson Brewer Jr. (Writer) Bette Davis?s bravura, moving-but-never-morbid performance as Judith Traherne, a dying heiress determined to find happiness in her few remaining months, remains a three-hankie classic. But that success would never have happened if Davis hadn?t pestered studio brass to buy Dark Victory?s story rights. Jack Warner finally did so skeptically. Who wants to see a dame go blind? he asked. Almost everyone: Dark Victory was Davis? biggest box-office hit yet and garnered Academy Award nominations for 1939?s Best Picture, Actress and Original Score (Max Steiner). |
 |
Brain Tumors: An Encyclopedic Approach by Andrew H. Kaye MD MBBS FRACS (Editor), Edward R. Laws MD FACS (Editor) (Churchill Livingstone) Second author, Edward R. Laws, Jr. Extensive reference providing a systematic updating of the chapters from the previous edition, c1995, with a number of new contributors. Retains an encyclopedic approach and includes key points and key references where appropriate. Color and halftone illustrations. For neurosurgeons. |
 |
Cure Brain Tumor Long Sleeve T-shirt Large White by Shop Zeus |
 |
Brain ElevateTM Vegetarian - 60 Count by NOW Foods For centuries, Eastern civilizations have relied on Huperzine as a broadly useful herbal health aid. It was only recently discovered however, that this rare moss extract has the ability to prevent the breakdown of acetylcholine - a chemical in the brain that plays a substantial role in cognitive clarity and memory function. By combining this extract with a proprietary blend of other natural substances that help protect neuronal tissue and improve blood flow (RoseOx®, Ginko Biloba, L-Glutamine and more), NOW Brain Elevate Vcaps may be advantageous for elevating cognitive performance. |
| © 2009 BrightSurf.com |